Cargando…

Tall cell variant papillary thyroid carcinoma in Saudi patients: A clinicopathological and outcomes analysis

OBJECTIVES: To evaluate the clinicopathological features and treatment outcomes of papillary thyroid carcinoma tall cell variant (PTC-TCV) in Saudi population. METHODS: This retrospective study were medical records of 776 treated PTC patients between December 2007 and 2015, at King Fahad Medical Cit...

Descripción completa

Detalles Bibliográficos
Autores principales: Al-Qahtani, Khalid H., Tunio, Mutahir A., Asiri, Mushabbab Al, Bayoumi, Yasser, Alshehri, Walaa A., Aljohani, Naji J., Ali, Ahmed Amir, Fatani, Hanadi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Saudi Medical Journal 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5303799/
https://www.ncbi.nlm.nih.gov/pubmed/27761560
http://dx.doi.org/10.15537/smj.2016.11.15480
_version_ 1782506762138550272
author Al-Qahtani, Khalid H.
Tunio, Mutahir A.
Asiri, Mushabbab Al
Bayoumi, Yasser
Alshehri, Walaa A.
Aljohani, Naji J.
Ali, Ahmed Amir
Fatani, Hanadi
author_facet Al-Qahtani, Khalid H.
Tunio, Mutahir A.
Asiri, Mushabbab Al
Bayoumi, Yasser
Alshehri, Walaa A.
Aljohani, Naji J.
Ali, Ahmed Amir
Fatani, Hanadi
author_sort Al-Qahtani, Khalid H.
collection PubMed
description OBJECTIVES: To evaluate the clinicopathological features and treatment outcomes of papillary thyroid carcinoma tall cell variant (PTC-TCV) in Saudi population. METHODS: This retrospective study were medical records of 776 treated PTC patients between December 2007 and 2015, at King Fahad Medical City and King Khalid University Hospital, Riyadh, Kingdom of Saudi Arabia was probed for PTC-TCV. Total 42 (5.4%) patients were found to have PTC-TCV, which were investigated for demographic, symptoms, histopathological features, and treatment outcomes locoregional control (LRC), distant metastasis control (DMC), disease free survival (DFS), and overall survival (OS) rates. RESULTS: Mean age of cohort was 52.3 years (range: 46-80), with female predominance (73.8%). Mean tumor size was 3.62 cm (range: 0.4-10). Rates of LVSI (59.5%), positive pathological lymph nodes (66.7%), multifocality (42.9%) and extrathyroidal extension, (45.3%). Median follow-up was 37.4 months (range: 6-60). Local recurrence rate were seen in 6/42 (14.2%) patients and 8/42 (19%) developed distant metastasis. The 5 year rates of LRC (82.3%), DMC (77.8%), DFS (69.2%), and OS (86.7%) multivariate analysis showed PTC-TVC as an important independent prognosticator (odds ratio: 4.2; 95% confidence interval: 1.79-7.3; p=0.03) CONCLUSION: Papillary thyroid carcinoma tall cell variant is associated with aggressive biological behavior.
format Online
Article
Text
id pubmed-5303799
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Saudi Medical Journal
record_format MEDLINE/PubMed
spelling pubmed-53037992017-02-16 Tall cell variant papillary thyroid carcinoma in Saudi patients: A clinicopathological and outcomes analysis Al-Qahtani, Khalid H. Tunio, Mutahir A. Asiri, Mushabbab Al Bayoumi, Yasser Alshehri, Walaa A. Aljohani, Naji J. Ali, Ahmed Amir Fatani, Hanadi Saudi Med J Original Article OBJECTIVES: To evaluate the clinicopathological features and treatment outcomes of papillary thyroid carcinoma tall cell variant (PTC-TCV) in Saudi population. METHODS: This retrospective study were medical records of 776 treated PTC patients between December 2007 and 2015, at King Fahad Medical City and King Khalid University Hospital, Riyadh, Kingdom of Saudi Arabia was probed for PTC-TCV. Total 42 (5.4%) patients were found to have PTC-TCV, which were investigated for demographic, symptoms, histopathological features, and treatment outcomes locoregional control (LRC), distant metastasis control (DMC), disease free survival (DFS), and overall survival (OS) rates. RESULTS: Mean age of cohort was 52.3 years (range: 46-80), with female predominance (73.8%). Mean tumor size was 3.62 cm (range: 0.4-10). Rates of LVSI (59.5%), positive pathological lymph nodes (66.7%), multifocality (42.9%) and extrathyroidal extension, (45.3%). Median follow-up was 37.4 months (range: 6-60). Local recurrence rate were seen in 6/42 (14.2%) patients and 8/42 (19%) developed distant metastasis. The 5 year rates of LRC (82.3%), DMC (77.8%), DFS (69.2%), and OS (86.7%) multivariate analysis showed PTC-TVC as an important independent prognosticator (odds ratio: 4.2; 95% confidence interval: 1.79-7.3; p=0.03) CONCLUSION: Papillary thyroid carcinoma tall cell variant is associated with aggressive biological behavior. Saudi Medical Journal 2016-11 /pmc/articles/PMC5303799/ /pubmed/27761560 http://dx.doi.org/10.15537/smj.2016.11.15480 Text en Copyright: © Saudi Medical Journal http://creativecommons.org/licenses/by-nc-sa/3.0 This is an open-access article distributed under the terms of the Creative Commons Attribution-Noncommercial-Share Alike 3.0 Unported, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Al-Qahtani, Khalid H.
Tunio, Mutahir A.
Asiri, Mushabbab Al
Bayoumi, Yasser
Alshehri, Walaa A.
Aljohani, Naji J.
Ali, Ahmed Amir
Fatani, Hanadi
Tall cell variant papillary thyroid carcinoma in Saudi patients: A clinicopathological and outcomes analysis
title Tall cell variant papillary thyroid carcinoma in Saudi patients: A clinicopathological and outcomes analysis
title_full Tall cell variant papillary thyroid carcinoma in Saudi patients: A clinicopathological and outcomes analysis
title_fullStr Tall cell variant papillary thyroid carcinoma in Saudi patients: A clinicopathological and outcomes analysis
title_full_unstemmed Tall cell variant papillary thyroid carcinoma in Saudi patients: A clinicopathological and outcomes analysis
title_short Tall cell variant papillary thyroid carcinoma in Saudi patients: A clinicopathological and outcomes analysis
title_sort tall cell variant papillary thyroid carcinoma in saudi patients: a clinicopathological and outcomes analysis
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5303799/
https://www.ncbi.nlm.nih.gov/pubmed/27761560
http://dx.doi.org/10.15537/smj.2016.11.15480
work_keys_str_mv AT alqahtanikhalidh tallcellvariantpapillarythyroidcarcinomainsaudipatientsaclinicopathologicalandoutcomesanalysis
AT tuniomutahira tallcellvariantpapillarythyroidcarcinomainsaudipatientsaclinicopathologicalandoutcomesanalysis
AT asirimushabbabal tallcellvariantpapillarythyroidcarcinomainsaudipatientsaclinicopathologicalandoutcomesanalysis
AT bayoumiyasser tallcellvariantpapillarythyroidcarcinomainsaudipatientsaclinicopathologicalandoutcomesanalysis
AT alshehriwalaaa tallcellvariantpapillarythyroidcarcinomainsaudipatientsaclinicopathologicalandoutcomesanalysis
AT aljohaninajij tallcellvariantpapillarythyroidcarcinomainsaudipatientsaclinicopathologicalandoutcomesanalysis
AT aliahmedamir tallcellvariantpapillarythyroidcarcinomainsaudipatientsaclinicopathologicalandoutcomesanalysis
AT fatanihanadi tallcellvariantpapillarythyroidcarcinomainsaudipatientsaclinicopathologicalandoutcomesanalysis